Subcutaneous Tocilizumab May Be Less Effective than Intravenous Tocilizumab in the Treatment of Juvenile Idiopathic Arthritis-associated Uveitis.
Department of Rheumatology, Pediatric Rheumatology Unit, Hospital Universitario Vall d'Hebron.
Estefania
E
Quesada-Masachs
Department of Rheumatology, Pediatric Rheumatology Unit, Hospital Universitario Vall d'Hebron, Barcelona, Spain. cmodesto@vhebron.net.
Consuelo Modesto
CM
Caballero
D000293:Adolescent; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D016896:Treatment Outcome; D014605:Uveitis / Q000188:drug therapy*
D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; C502936:tocilizumab